中药逆转EGFR-TKIs治疗NSCLC耐药的研究进展  

Research Progress in Traditional Chinese Medicine for Altering EGFR-TKIs Resistance

作　　者：叶青[1] 王瑞平[2] 

机构地区：[1]南京中医药大学附属医院,江苏南京210029 [2]江苏省中医院,江苏南京210029

出　　处：《中药新药与临床药理》2016年第4期583-587,共5页Traditional Chinese Drug Research and Clinical Pharmacology

基　　金：国家中医临床研究基地业务建设科研专项课题(JDZX2012087);江苏省中医药领军人才项目(LJ200908);江苏省卫生计生委课题(BJ14013)

摘　　要：分子靶向药物表皮生长因子受体酪氨酸酶抑制剂(Epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKIs)是具有EGFR突变的晚期非小细胞肺癌(NSCLC)的有效治疗手段。然而,大部分患者在接受治疗一段时间后出现获得性耐药,严重阻碍了治疗的顺利进行。中药在逆转EGFR-TKIs耐药已进行了大量的研究,并显示其可行性和可应用性。本文在阐述EGFR-TKIs耐药机制的基础上,综述近年来中药单体和复方逆转EGFR-TKIs耐药的研宄进展。Lung cancer is one of the main causes of human deaths. Epidermal growth factor receptor tyrosine kinase inhibitors（EGFR-TKIs）is an effective therapy for advanced non-small cell lung cancer（NSCLC）with EGFR mutations.However,resistance to EGFR-TKIs occurred in the majority of patients after months of treatment,which seriously hindered the treatment to be continued. Large amount of research has revealed the feasibility and applicability of traditional Chinese medicine（TCM）in altering EGFR-TKIs resistance. Here,we discussed the EGFR-TKIs-resistance mechanism and reviewed the research progress in TCM for altering EGFR-TKIs resistance.

关 键 词：中药 非小细胞肺癌 表皮生长因子受体酪氨酸酶抑制剂 耐药 

分 类 号：R285.5[医药卫生—中药学]